March 26, 2007 – Biosite agreed to be acquired by Beckman Coulter for $85 per share, a premium of more than 50% to its closing price on Friday; Osiris said a stem cell treatment, Provacel, was safe and effective in an trial for heart disease; Lilly was awarded orphan drug status in Europe for a cancer drug; Sanofi-Aventis said its weight-loss drug Acomplia will face an FDA Advisory Committee panel on June 13, 2007; Merck won approval in Europe for Januvia, its drug for type 2 diabetes; Schering-Plough and Merck will collaborate to develop another combination cholesterol drug; Indevus predicted positive results from the Phase III trial of a drug for hypogonadism; Centocor and Schering-Plough received an extended indication in Europe for Remicade; Crucell and DSM Biologics have out-licensed technology to a Taiwan firm; and Isis reported positive data on its cholesterol treatment. The Centient Biotech 200™ edged 4 points lower to 3893, a decrease of .09%. More details...
